Author highlights Eli Lilly's financial interest in Acrivon Therapeutics' ACR-368, including milestone payments, royalties, and a right to reacquire the drug, framing ACRV as oversold.
ACRV — LONG The author argues that Eli Lilly's retained financial interest in Acrivon's ACR-368 (prexasertib), including potential milestone payments, royalties, and a contractual right to negotiate first to reacquire the drug, makes ACRV an attractive oversold opportunity. The mechanism is that Lilly's vested interest could lead to a buyout or reacquisition, providing upside. No specific timeframe or risk is stated.
Eli Lilly retains a Key financial interest in the success of Acrivon's ACR-368 (prexasertib) through potential milestone payments and royalties, and crucially, it has a contractual right to negotiate first to reacquire the drug.
This Reddit post, published January 13, 2026, features u/Choice_Client_5400 discussing ACRV. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Choice_Client_5400 · Tickers: ACRV